Why is the Noxopharm (ASX:NOX) share price up 4% on Monday?

There's more clinical trial momentum out of the drug developer's corner today.

| More on:
medical research laboratory assistant examines solutions in test tubes

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Noxopharm Ltd (ASX: NOX) share price is edging higher this afternoon and is currently trading up 2.8% at 55 cents apiece.

Shares in the drug development company are on the move after it released a key announcement regarding its lead drug candidate Veyonda.

Here's what we know out of Noxopharm's corner today.

What was announced?

The company advised it had received "notices of allowance" from both the Australian and European patent offices covering use of the active ingredient in Veydona, idronoxil.

Veydona is the company's lead drug candidate currently in Phase 2 safety and efficacy clinical trials. The company has the end goal of turning the drug into a label that's indicated in all types of cancer treatment.

Specifically, the patent governs the use of Veydona to "allow dosages of chemotherapy to be lowered to safer levels without compromising their anti-cancer effectiveness".

This involves a particular method where Veydona is supplied with a low dose of chemotherapy drugs in the treatment of various cancers.

Noxopharm is confident the combination therapy can "deliver an even stronger anti-cancer response at the same time as offering the same benefit".

The end result will be that Veydona may be offered as a combination therapy to patients unable to undergo full-strength chemotherapy.

The need, Noxopharm says, originates from the wide-ranging side effects of the current care standard through the use of chemotherapy compounds known as "platinum drugs".

This category ranks among the gold standard of commonly used chemotherapy drugs.

In the population taking these platinum drugs, Noxpharm explained that adverse side effects cause a reduction in therapy in around 30% of cases. They also result in 10% of patients having to stop therapy altogether.

The company says idronoxil, through the Veydona label, purportedly enhances chemotherapy "up to a magnitude of 1,000 times…without increasing the sensitivity to healthy cells to the damaging effects of the drugs".

This concept was proved back in April in the company's CEP-1 study which investigated Veydona's effects when administered this way.

A new study, CEP-2, followed further building on the results obtained from the original clinical trial. Results will be available in due course.

The patent granted today builds on other patent positions it has filed for in both radiotherapy and immunotherapy earlier in the year.

What did management say?

Speaking on the announcement, Noxopharm's CEO Graham Kelly said:

A high proportion of cancer patients are deprived of the benefits of chemotherapies because of toxic side-effects. The development of side-effects leads to drug dosages being lowered or stopped altogether. Other patients either are too ill or too elderly or just unwilling to even start chemotherapy. That is the gap that we see Veyonda filling by allowing the patient to still gain the benefit of the chemotherapy but at dosages that are much better tolerated. With an estimated US$150 billion spent globally each year on chemotherapy, that gap represents a very major medical need and commercial opportunity.

Regarding other patent filings and the company's growth vision, Kelly added:

Allowance of these claims is a major milestone in the Company's aim to see Veyonda become a standard of care companion drug in oncology for chemotherapy, radiotherapy and immunotherapy. With the radiotherapy (ASX Announcement 27 September 2021) and immunotherapy patent positions looking strong, the allowances announced today represent an important step towards achieving that eventual aim, something that we are confident will be attractive to major pharma companies with strong chemotherapy drug portfolios.

Noxopharm share price snapshot

The Noxopharm share price has had a difficult year to date, having posted a return of 12% since January 1.

As such, it has only climbed around 9% in the last 12 months and is in the red by around 2% in the last month.

These results have lagged the S&P/ASX 200 Index (ASX: XJO)'s return of around 21% in the past year.

The author Zach Bristow has no positions in any of the socks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

asx share price boosted by us investment represented by hand waving US flag across winning athlete
Best Shares

Here are the best-performing ASX 200 shares since the US election result

We reveal the 10 ASX stocks that have had the highest share price gains since the US Presidential election.

Read more »

a man sits back from his laptop computer with both hands behind his head feeling happy to see the Brambles share price moving significantly higher today
Industrials Shares

Up 39% in a year, is there more growth to come for this ASX 200 share?

IML Equity Analyst Josh Freiman shares his views on a major ASX 200 industrial stock.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Catapult, Flight Centre, Nufarm, and Xero shares are storming higher today

These shares are having a strong session on Thursday. But why? Let's find out.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 made it three-for-three losses in a row this Wednesday.

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Brickworks, James Hardie, Megaport, and OFX shares are charging higher today

These shares are having a good time on hump day. But why?

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors endured another day of selling this Tuesday.

Read more »

Man pointing at a blue rising share price graph.
Technology Shares

Guess which ASX 300 tech stock is already up 64% in November!

The ASX 300 tech stock is surging higher this month. But why?

Read more »